Luteal Phase and Embryonic Development in GnRH-Agonist/hMG-Cycles for In Vitro Fertilization
The combined GnRH-agonist hMG-stimulation has now become a worthwhile tool as a second line therapy in vitro fertilization (IVF) under special conditions such as premature LH-surge and hyperandrogenemia. Several authors even propose this treatment as a first line therapy with an increased overall pregnancy rate.
KeywordsPregnancy Rate Granulosa Cell Luteal Phase Ovarian Stimulation Progesterone Level
Unable to display preview. Download preview PDF.
- Testart, J., Forman, R., Belaisch-Allart, J., Volante, M., Hazout, A., Strubb, N., and Frydman, R., 1989, Embryo quality and uterine receptivity in in vitro fertilization cycles with or without agonists of gonadotropin-releasing hormone, Human Reprod., 4:198.Google Scholar